Literature DB >> 34964477

Confounding of Antipsychotic Discontinuation Studies by Withdrawal-Related Relapse.

Mark Abie Horowitz1,2, Robin M Murray3, David Taylor3,4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34964477      PMCID: PMC8886601          DOI: 10.1093/schbul/sbab146

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  7 in total

Review 1.  Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.

Authors:  J Moncrieff
Journal:  Acta Psychiatr Scand       Date:  2006-07       Impact factor: 6.392

2.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Authors:  Lex Wunderink; Roeline M Nieboer; Durk Wiersma; Sjoerd Sytema; Fokko J Nienhuis
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

3.  Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Authors:  Stefan Leucht; Magdolna Tardy; Katja Komossa; Stephan Heres; Werner Kissling; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2012-05-03       Impact factor: 79.321

4.  Tapering Antipsychotic Treatment.

Authors:  Mark Abie Horowitz; Robin M Murray; David Taylor
Journal:  JAMA Psychiatry       Date:  2021-02-01       Impact factor: 21.596

5.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

6.  Predictors of Lack of Relapse After Random Discontinuation of Oral and Long-acting Injectable Antipsychotics in Clinically Stabilized Patients with Schizophrenia: A Re-analysis of Individual Participant Data.

Authors:  Georgios Schoretsanitis; John M Kane; Christoph U Correll; Jose M Rubio
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.